United States Assisted Reproductive Technology Market Forecast 2025–2033

According to Renub Research United States Assisted Reproductive Technology (ART) Market is projected to grow significantly, reaching US$ 9.31 billion by 2033, up from US$ 6.01 billion in 2024. This reflects a strong CAGR of 4.98% between 2025 and 2033. Increasing infertility rates, strong public awareness campaigns, technological breakthroughs in reproductive science, rising acceptance of fertility treatments, expanded insurance coverage, and growing use of genetic testing and embryo preservation are key forces driving market expansion.

Overview of the United States Assisted Reproductive Technology Market

Assisted Reproductive Technology (ART) refers to medical treatments used to address infertility by manipulating sperm, eggs, or embryos to achieve pregnancy. Common ART procedures include:

• In Vitro Fertilization (IVF)
• Intracytoplasmic Sperm Injection (ICSI)
• Artificial Insemination (AI-IUI)
• Embryo cryopreservation and egg freezing
• Sperm and egg donation

ART is primarily used when other reproductive treatments fail or when infertility is caused by age-related decline, genetic predispositions, or unexplained reproductive issues. These procedures are performed in specialized fertility clinics under the supervision of reproductive endocrinologists, giving millions of individuals and couples the chance to achieve parenthood.

Growing awareness and education about infertility are major contributors to market growth. Public health campaigns, social media outreach, and advocacy from nongovernmental organizations have played a central role in normalizing fertility treatments. Additionally, celebrities openly discussing IVF, surrogacy, and fertility preservation have helped reduce stigma and increase treatment acceptance.

The industry is also witnessing stronger collaborations among research groups, professional societies, and technology companies. A notable example is the partnership between the Society for Reproductive Biologists and Technologists (SRBT) and the American Society for Reproductive Medicine (ASRM) to establish the ASRM Clinical Embryology Learning Laboratory (“CELL”), launched in October 2024. Initiatives like this help enhance training and standardization across fertility laboratories nationwide.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=united-states-assisted-reproductive-technology-market-p.php

Growth Drivers of the United States Assisted Reproductive Technology Market

Growing Demand for PGT (Preimplantation Genetic Testing) and Genetic Screening

Preimplantation Genetic Testing (PGT) is increasingly integrated into IVF procedures to screen for chromosomal abnormalities and genetic disorders. Advanced methods using Next-Generation Sequencing (NGS) allow clinicians to identify the healthiest embryos with greater sensitivity, improving the chances of successful implantation.

PGT is particularly popular among:

• Women of advanced maternal age
• Patients undergoing multiple unsuccessful IVF cycles
• Couples with known hereditary conditions

The rising interest in precision medicine means patients now prefer personalized reproductive treatment strategies. PGT-A (aneuploidy testing) significantly enhances success rates by reducing miscarriages and maximizing live births, thus expanding market adoption.

Rapid Developments in AI-Powered IVF and Laboratory Automation

Artificial Intelligence (AI) and automation have become transformative forces within the fertility industry. AI applications improve embryo selection accuracy, reduce human intervention, and streamline laboratory operations. Key advancements include:

• Time-lapse imaging platforms such as EmbryoScope
• AI models that analyze embryo development patterns
• Automated storage systems reducing sample mishandling
• Predictive analytics optimizing patient treatment protocols

Companies such as TMRW Life Sciences and Alife Health are pioneering automated embryo management and decision-support systems.

In July 2024, Canadian company Hamilton Thorne Ltd. launched EmbryoView Pro, an AI-driven monitoring system designed to provide instant embryo assessments. This technology enhances accuracy and improves clinical outcomes, aligning with the growing demand for technologically advanced reproductive medicine.

Rising Popularity of Fertility Preservation and Egg Freezing

Egg freezing—once a niche procedure—has become mainstream due to social, professional, and medical factors. Women increasingly postpone motherhood due to career aspirations, financial considerations, or lifestyle choices. Advances in vitrification, the modern method of flash-freezing eggs, have improved post-thaw survival rates and increased IVF success.

Key factors boosting egg freezing demand include:

• Employer-sponsored fertility benefits from companies like Google, Meta, and Apple
• Greater awareness of age-related fertility decline
• Expanded fertility preservation campaigns led by clinics
• Increased acceptance of elective egg freezing among younger women

This trend represents a broader cultural shift toward proactive reproductive planning. Many clinics now market egg freezing as a form of “reproductive insurance,” allowing women greater control over future family-building choices.

Challenges Impacting Market Growth

High Cost of ART Treatments

Despite growing demand, the cost of ART in the United States remains a major barrier. A single IVF cycle can range from US$ 12,000 to US$ 20,000, excluding additional expenses such as:

• Hormonal medications
• PGT and genetic testing
• Embryo storage fees
• Supplemental procedures such as ICSI

Multiple cycles are often required to achieve successful pregnancy, creating a substantial financial burden. Limited insurance coverage across many states restricts accessibility, especially for middle-income and underserved populations. This cost barrier reinforces socioeconomic inequalities in reproductive healthcare availability.

Complex Regulatory Environment

The U.S. ART landscape faces considerable challenges due to non-uniform regulations. The absence of consistent federal oversight leads to differences in clinic protocols, reporting standards, ethical practices, and insurance requirements across states.

Key concerns include:

• Inconsistent treatment quality
• Variability in embryo handling standards
• Limited enforcement of reporting accuracy
• Ethical debates surrounding embryo storage and genetic editing

These regulatory discrepancies create uncertainty for clinics and patients alike, slowing the rate of innovation and standardization within the industry.

United States Assisted Reproductive Technology Market Segmentation

Technology Segmentation

1. In Vitro Fertilization (IVF)
   The dominant ART technology, IVF is widely used to treat complex infertility cases, offering high success rates through embryo culture and transfer.
2. Artificial Insemination (AI-IUI)
   Often used as the first-line fertility treatment due to its affordability and non-invasive nature.
3. Frozen Embryo Transfer (FET)
   Increasingly popular due to improved embryo survival rates from vitrification and better outcomes compared to fresh transfers.
4. Other Technologies
   Includes sperm donation, egg donation, ICSI, and assisted hatching.

End Use Segmentation

1. Hospitals
   Large hospitals offer comprehensive ART services with integrated medical support.
2. Fertility Clinics
   Specialized centers dominate the ART landscape due to advanced equipment, skilled embryologists, and customized treatment packages.
3. Other End Users
   Includes research institutions, reproductive endocrinology centers, and donor agencies.

Key Company Profiles and Competitive Landscape

The U.S. ART market is highly competitive, with leading players focused on innovation, lab automation, genetic testing solutions, and expanded clinical networks.
Major companies covered include:

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical, Inc.
• FUJIFILM Irvine Scientific, Inc.
• Cryolab Ltd.
• Vitrolife AB
• Merck KGaA
• Ferring B.V.

Each company is analyzed across four viewpoints:

1. Company Overview
2. Key Personnel
3. Recent Developments & Strategic Initiatives
4. Sales Performance & Market Contribution

These organizations are investing heavily in embryology training platforms, advanced culture media, diagnostic tools, cryopreservation technologies, and AI systems to strengthen their market positions.

Conclusion

The United States Assisted Reproductive Technology Market is on a clear path of sustained growth through 2033. Driven by rising infertility rates, improved technological capabilities, changing societal attitudes, and growing support for fertility preservation, the market continues to expand across all technology and end-user segments.

While high treatment costs and regulatory inconsistencies remain challenges, innovation in AI, PGT, vitrification, and embryo monitoring systems is enabling higher success rates and improved patient outcomes.

With demand accelerating, the U.S. will remain one of the largest and most technologically advanced ART markets globally.